Login/Sign Up
MRP ₹72500
(Inclusive of all Taxes)
₹8700.0 Cashback (12%)
Provide Delivery Location
Online payment accepted
Whats That
About Yervoi 5 mg/ml Infusion
Yervoi 5 mg/ml Infusion is an anti-cancer medicine used in the treatment of various types of cancers. Cancer is a disease caused by the abnormal growth of cells that divide uncontrollably. This medicine is used in treating metastatic melanoma, advanced renal cell carcinoma in combination with nivolumab, hepatocellular carcinoma in patients who have previously been treated with sorafenib, colorectal cancer, metastatic non-small cell lung cancer, and malignant pleural mesothelioma.
Yervoi 5 mg/ml Infusion contains Ipilimumab, which belongs to the class of CTLA-4 monoclonal antibody. It works by inhibiting the action of a human cytotoxic T-lymphocyte antigen 4 molecule, thereby stopping the abnormal growth of cancer cells.
Yervoi 5 mg/ml Infusion may cause certain side effects such as diarrhoea, decreased appetite, nausea, vomiting, tiredness, itching, rash, headache, fever, decreased weight, and dizziness. Inform your doctor if any of these side effects bother you. Yervoi 5 mg/ml Infusion will be administered by an oncologist with experience in administering chemotherapeutic agents in the hospital setting. Avoid self-administration.
If you are allergic to Yervoi 5 mg/ml Infusion or its components, inform your doctor. Before taking Yervoi 5 mg/ml Infusion, inform your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis, Crohn’s disease, or a history of organ transplants. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. If you are breastfeeding, inform your doctor before receiving Yervoi 5 mg/ml Infusion.
Uses of Yervoi 5 mg/ml Infusion
Directions for Use
Medicinal Benefits
Yervoi 5 mg/ml Infusion contains Ipilimumab, which is used in treating different types of cancers. It works by inhibiting the action of a human cytotoxic T-lymphocyte antigen 4 molecule (CTLA-4) that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other parts of the body. In this way, Yervoi 5 mg/ml Infusion stops the body's production, spread and growth of cancerous cells.
Storage
Drug Warnings
To treat your condition effectually, continue taking Yervoi 5 mg/ml Infusion for the period that your doctor has prescribed. Yervoi 5 mg/ml Infusion may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, nephritis, endocrinopathies, pneumonitis, and dermatologic reactions. It may also cause infusion-related reactions in some patients. Discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders and autoimmune disorders such as ulcerative colitis or Crohn’s disease while receiving Yervoi 5 mg/ml Infusion. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Diet & Lifestyle Advise
Side Effects of Yervoi 5 mg/ml Infusion
Habit Forming
Therapeutic Class
We provide you with authentic, trustworthy and relevant information
Drug-Diseases Interactions
Login/Sign Up
Yervoi 5 mg/ml Infusion contains Ipilimumab, which works by inhibiting the action of a human cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule that causes the multiplication of cancerous cells.
It is safe to use Yervoi 5 mg/ml Infusion in patients with diabetes. However, if you are diabetic, inform your doctor before starting the treatment with Yervoi 5 mg/ml Infusion.
Drug-Drug Interactions Checker List
Special Advise
Disease/Condition Glossary
Renal Cell Carcinoma: Also known as kidney cancer. It is the most common type of cancer seen in adults. This condition occurs when cancer/ malignant cells grow uncontrollably in the kidney and form a tumor. Advanced kidney cancer (metastatic renal cell carcinoma) occurs when the malignant cells spread to other parts of the body. Symptoms include red, orange, or pink-coloured urine due to the presence of blood in the urine.
Hepatocellular carcinoma: Also known as liver cancer. It occurs when the cancer/ malignant cells grow out of control. This infects the liver, destroys the liver cells and affects the ability of the liver to work properly. Symptoms may include abdominal pain, loss of appetite, weight loss, and pale bowel motions.
Colorectal cancer: Also known as colon cancer (growth of cancer cells in the colon) or rectal cancer (cancer cells grow in the rectum area), is a condition in which the cancerous or malignant cells grow out of control in the colon or rectum. Symptoms may include diarrhoea, constipation, bloody stools, change in bowel habits, abdominal discomfort, etc.
Metastatic Malignant Melanoma: Melanoma is a type of skin cancer in which the cancer cells grow in melanocytes. It is mainly caused by harmful UV radiation from the sun. When the cancer cells spread to other parts of the body, it is known as Metastasis. Malignant melanoma is common in fair-skinned and freckled individuals. It results in mole formation, typically on the skin of the face.
Malignant pleural mesothelioma: It is a type of cancer that develops in the mesothelium (a lining that covers the outer surface of organs), predominantly caused by exposure to asbestos. Symptoms of mesothelioma in the lining of the lungs include chest pain, shortness of breath, extreme tiredness, persistent cough, loss of appetite, unexplained weight loss, fever and sweating, particularly at night.
Non-Small Cell Lung Cancer (NSCLC): Lung cancer is defined as an uncontrollable growth of abnormal cells in one or both lungs. These abnormal cells disturb lung cell functions and do not develop into healthy lung tissue. The most common form of lung cancer is non-small cell lung cancer (NSCLC). It happens when cells that form the lining of the lung start growing uncontrollably. Cancerous cells of the lung spread off and travel through the bloodstream to distant regions of the body and grow. It is mostly seen in persons who smoke. Symptoms may include chest pain, weight loss, hoarseness, and difficulty breathing.
Have a query?
Buy best Neoplastic Disorders products by
Intas Pharmaceuticals Ltd
Natco Pharma Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Celon Laboratories Pvt Ltd
Sun Pharmaceutical Industries Ltd
Alkem Laboratories Ltd
United Biotech Pvt Ltd
Zydus Cadila
Zydus Healthcare Ltd
Neon Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Mylan Pharmaceuticals Pvt Ltd
BDR Pharmaceuticals Internationals Pvt Ltd
Emcure Pharmaceuticals Ltd
Adley Formulations
Samarth Life Sciences Pvt Ltd
Hetero Drugs Ltd
Torrent Pharmaceuticals Ltd
Fresenius Kabi India Pvt Ltd
Pfizer Ltd
Admac Lifesciences(Oncology)
Adley Pharmaceuticals Ltd
Novartis India Ltd
Halsted Pharma Pvt Ltd
Getwell Life Sciences India Pvt Ltd
Lupin Ltd
Cadila Healthcare Ltd
Hetero Healthcare Pvt Ltd
GLS Pharma Ltd
Reliance Formulation Pvt Ltd
Abbott India Ltd
Aimcad Biotech Pvt Ltd
Astra Zeneca Pharma India Ltd
Therdose Pharma Pvt Ltd
Axiommax Oncology Pvt Ltd
Biochem Pharmaceutical Industries Ltd
Khandelwal Laboratories Pvt Ltd
Msn Laboratories Pvt Ltd
Aureate Healthcare
Caitlin Oncology
Dabur India Ltd
Zee Laboratories Ltd
Sarabhai Chemicals (India) Pvt Ltd
Wembrace Biopharma Pvt Ltd
Delarc Pharmaceuticals Pvt Ltd
Medaegis Biotek Pvt Ltd
Panacea Biotec Ltd
RPG Life Sciences Ltd
Shilpa Medicare Ltd
Getwell Oncology Pvt Ltd
Ipca Laboratories Ltd
Miracalus Pharma Pvt Ltd
Biocon Ltd
Cadila Pharmaceuticals Ltd
Eli Lilly and Company (India) Pvt Ltd
Ferring Pharmaceuticals Pvt Ltd
Fresenius Kabi Oncology Ltd
Getwell Pharmaceutical Pvt Ltd
Maximal Healthcare Pvt Ltd
Boehringer Ingelheim India Pvt Ltd
Del Trade International Pvt Ltd
Sayre Therapeutics Pvt Ltd
Akumentis Healthcare Ltd
Corona Remedies Pvt Ltd
Eisai Pharmaceuticals India Pvt Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Hilfen Pharmaceuticals Pvt Ltd
Johnson & Johnson Pvt Ltd
Mankind Pharma Pvt Ltd
Merck Ltd
Oncostar Pharma Pvt Ltd
Rhone Poulenc Rorer India Pvt Ltd
Vhb Life Sciences Inc
Zuventus Healthcare Ltd
Admac Pharma Ltd
Adonis Laboratories Pvt Ltd
Alniche Life Sciences Pvt Ltd
BPRL Pvt Ltd
Caitlin Life Care
Dr Care
German Remedies Ltd
Janssen Pharmaceuticals Pvt Ltd
MEDICAMEN BIOTECH LTD
Maxis Healthcare (I) Pvt Ltd
Pharm Products Pvt Ltd
Accord Life Spec Pvt Ltd
Amps Biotech Biotech Pvt Ltd
Aphia Healthcare
Astellas Pharma India Pvt Ltd
Bangalore Pharmaceutical and Research Laboratory Pvt Ltd (BPRL)
Bharat Serums and Vaccines Ltd
Cellgen Biopharma
Cosmic Life Sciences
Daris Biocare
East West Pharma India Pvt Ltd
Hillrock Biotech Pvt Ltd
Lucien Life Sciences
Maneesh Pharmaceuticals Ltd
Medilief Bioscience Pvt Ltd
Alcohol
Consult your doctor
It is unknown whether Yervoi 5 mg/ml Infusion interacts with alcohol. Consult your doctor.
Pregnancy
Unsafe
Yervoi 5 mg/ml Infusion is not recommended for use in pregnancy as it may cause embryo-fetal toxicity and harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before taking Yervoi 5 mg/ml Infusion. You should not become pregnant while you are taking Yervoi 5 mg/ml Infusion for at least 3 months from the last dose of Yervoi 5 mg/ml Infusion. Using effective birth control methods while on treatment with Yervoi 5 mg/ml Infusion is suggested.
Breast Feeding
Unsafe
Inform your doctor if you are intending to breastfeed. Breastfeeding should be avoided while getting Yervoi 5 mg/ml Infusion and for 3 months following the final dosage.
Driving
Not applicable
Yervoi 5 mg/ml Infusion will be administered to hospitalized patients.
Liver
Caution
If you have a pre-existing or a history of liver problems, tell your doctor before taking this medicine. Yervoi 5 mg/ml Infusion is known to cause hepatotoxicity when taken in combination with nivolumab. Notify your doctor if you notice any of the following symptoms: yellowing of your skin or whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach (abdomen); dark urine (tea-coloured); easier bleeding or bruising than usual. Your doctor may suggest tests to monitor your liver function while on treatment with this medicine.
Kidney
Caution
If you have a pre-existing or a history of kidney diseases, inform your doctor before taking Yervoi 5 mg/ml Infusion. It may cause kidney injury. Notify your doctor if you experience symptoms such as decreased urine output, blood in your urine, ankle edema, or lack of appetite.
Children
Unsafe
Yervoi 5 mg/ml Infusion is not recommended for use in children below 12 years, as the safety and efficacy have not been established.